First Time Loading...

Reata Pharmaceuticals Inc
NASDAQ:RETA

Watchlist Manager
Reata Pharmaceuticals Inc Logo
Reata Pharmaceuticals Inc
NASDAQ:RETA
Watchlist
Price: 172.36 USD Market Closed
Updated: May 1, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Reata Pharmaceuticals Inc

Revenue
23.5m USD
Cost of Revenue
-1.6m USD
Gross Profit
21.9m USD
Operating Expenses
-363.6m USD
Operating Income
-341.7m USD
Other Expenses
254m USD
Net Income
-87.6m USD

Margins Comparison
Reata Pharmaceuticals Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Reata Pharmaceuticals Inc
NASDAQ:RETA
6.5B USD
93%
-1 455%
-373%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
741.6B USD
79%
30%
15%
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK
85%
45%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY
57%
6%
3%
US
Johnson & Johnson
NYSE:JNJ
348B USD
70%
29%
50%
US
Merck & Co Inc
NYSE:MRK
327.1B USD
74%
7%
1%
UK
AstraZeneca PLC
LSE:AZN
187B GBP
82%
19%
13%
CH
Novartis AG
SIX:NOVN
182B CHF
74%
27%
32%
CH
Roche Holding AG
SIX:ROG
175.9B CHF
73%
32%
20%
Country US
Market Cap 6.5B USD
Gross Margin
93%
Operating Margin
-1 455%
Net Margin
-373%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 741.6B USD
Gross Margin
79%
Operating Margin
30%
Net Margin
15%
Country DK
Market Cap 4T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
36%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country JP
Market Cap 82T JPY
Gross Margin
57%
Operating Margin
6%
Net Margin
3%
Country US
Market Cap 348B USD
Gross Margin
70%
Operating Margin
29%
Net Margin
50%
Country US
Market Cap 327.1B USD
Gross Margin
74%
Operating Margin
7%
Net Margin
1%
Country UK
Market Cap 187B GBP
Gross Margin
82%
Operating Margin
19%
Net Margin
13%
Country CH
Market Cap 182B CHF
Gross Margin
74%
Operating Margin
27%
Net Margin
32%
Country CH
Market Cap 175.9B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Reata Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Reata Pharmaceuticals Inc
NASDAQ:RETA
6.5B USD
-112%
-15%
-71%
-232%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
741.6B USD
49%
9%
30%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK
88%
30%
79%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY
1%
1%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
348B USD
56%
23%
18%
14%
US
Merck & Co Inc
NYSE:MRK
327.1B USD
1%
0%
5%
1%
UK
AstraZeneca PLC
LSE:AZN
187B GBP
16%
6%
13%
11%
CH
Novartis AG
SIX:NOVN
182B CHF
28%
14%
16%
14%
CH
Roche Holding AG
SIX:ROG
175.9B CHF
40%
13%
29%
22%
Country US
Market Cap 6.5B USD
ROE
-112%
ROA
-15%
ROCE
-71%
ROIC
-232%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 741.6B USD
ROE
49%
ROA
9%
ROCE
30%
ROIC
16%
Country DK
Market Cap 4T DKK
ROE
88%
ROA
30%
ROCE
79%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country JP
Market Cap 82T JPY
ROE
1%
ROA
1%
ROCE
2%
ROIC
2%
Country US
Market Cap 348B USD
ROE
56%
ROA
23%
ROCE
18%
ROIC
14%
Country US
Market Cap 327.1B USD
ROE
1%
ROA
0%
ROCE
5%
ROIC
1%
Country UK
Market Cap 187B GBP
ROE
16%
ROA
6%
ROCE
13%
ROIC
11%
Country CH
Market Cap 182B CHF
ROE
28%
ROA
14%
ROCE
16%
ROIC
14%
Country CH
Market Cap 175.9B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More